Twb. Gehr et al., THE PHARMACOKINETICS OF PRAVASTATIN IN PATIENTS ON CHRONIC-HEMODIALYSIS, European Journal of Clinical Pharmacology, 53(2), 1997, pp. 117-121
Objective: The single-dose and steady-state pharmacokinetics of the HM
G CoA reductase inhibitor pravastatin and its two metabolites, SQ 31 9
06 and SQ 31 945, were evaluated in 12 hemodialysis patients. A single
20-mg i.v. dose was employed, followed by daily oral dosing of 20 mg
over four hemodialysis intervals. Results: No statistical differences
in the pharmacokinetics of pravastatin or-SQ 31 906 were evident when
comparing the first and last days of oral dosing with pravastatin. The
pharmacokinetic parameters of pravastatin and SQ 31 906 were similar
to those of healthy volunteers. SQ 31 945, the inactive polar metaboli
te, did accumulate in dialysis patients, as evidenced by an accumulati
on index of 1.7 +/- 1.0. Although metabolic clearance is the predomina
nt mode of elimination of pravastatin, hemodialysis clearances of prav
astatin, SQ 31 906 and SQ 31 945 will contribute to total body clearan
ce since dialytic clearance ranged from 40 to 80 ml . min(-1). Conclus
ion: Pravastatin can be safely administered in the usual dosages to su
bjects with renal failure on hemodialysis and no change in dosing is n
ecessary.